

# Palladium-Catalyzed Site-Selective C–H Arylation of 2,2'-Bipyridine-6-carboxamides via a Rollover Cyclometalation Pathway

## Table of Contents


<b>1. General Information</b>	S2
<b>2. Experimental Section</b>	S3-S28
2.1 Procedure for Synthesis of <b>S<sub>1</sub>-S<sub>3</sub></b>	S3
2.2 Procedure for Synthesis of <b>1a-1n</b>	S3-S7
2.3 Procedure for Synthesis of <b>3a-3h, 3m</b>	S7-S12
2.4 Procedure for Synthesis of <b>4a-4v</b>	S12-S23
2.5 Procedure for Synthesis of <b>I-1-I-2</b>	S23-S26
2.6 1 mmol-Scale Experiment of <b>3a</b>	S27
2.7 Reversibility and KIE Study	S27-S28
<b>3. References</b>	S28
<b>4. <sup>1</sup>H and <sup>13</sup>C NMR Spectra</b>	S28-S71

## 1. General Information

All solvents and chemicals were from Sigma-Aldrich, Tansoole, Energy Chemical, Acros and Alfa Aesar and used directly without further purification. All reactions were performed under an inert atmosphere of nitrogen in oven-dried glassware, unless otherwise stated. Flash column chromatography was performed over silica gel (300-400 mesh).  $^1\text{H}$  NMR spectra were recorded on a Bruker AVIII-500M spectrometers, Chemical shifts (in ppm) were referenced to  $\text{CHCl}_3$  ( $\delta = 7.26$  ppm) as an internal standard.  $^{13}\text{C}$  NMR spectra were obtained by using the same NMR spectrometers and were calibrated with  $\text{CDCl}_3$  ( $\delta = 77.0$  ppm). Chemical shifts ( $\delta$ ) are reported in ppm, and coupling constants (J) are in Hertz (Hz). Multiplicities are reported using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. High-resolution mass spectra (HRMS) were recorded on an Agilent 1290 Mass spectrometer using ESI-TOF (electrospray ionization-time of flight).


## 2.1 Procedure for Synthesis of S<sub>1</sub>-S<sub>3</sub>

S<sub>1</sub> and S<sub>2</sub> were synthesized following a literature procedure<sup>1</sup>. S<sub>3</sub> was synthesized following a literature procedure<sup>2</sup>.




(a) TFA, 1.5 equiv H<sub>2</sub>O<sub>2</sub>, rt, 2.5 h; (b) 2.5 equiv TMSCN, 1 equiv Benzoyl chloride, DCM, 5 d; (c) 4 equiv NaOH, C<sub>2</sub>H<sub>5</sub>OH/H<sub>2</sub>O = 2:1, reflux, 30 min; then HCl (1 M), pH = 3.8.

## 2.2 Procedure for Synthesis of 1a-1i



To a 50-mL oven-dried round-bottom flask were added S<sub>3</sub> (2,2'-bipyridine-6-carboxylic acid hydrochloride) (1 equiv, 4.24 mmol) in dichloromethane (25 mL). The solution was added appropriate amines (1.8 equiv, 7.63 mmol) and 2,4,6-collidine (1 equiv, 4.24 mmol), followed by addition of HATU (2 equiv, 8.48 mmol). The mixture was stirred at room temperature overnight. The crude mixture was quenched with aqueous NaHCO<sub>3</sub> and extracted with DCM (3 × 15 mL), dried over Mg<sub>2</sub>SO<sub>4</sub>, concentrated *in vacuo*. The crude amide product was purified by silica gel column chromatography to afford the pure product.

### N-butyl-[2,2'-bipyridine]-6-carboxamide (1a)




**1a**

The title compound **1a** was prepared from S<sub>3</sub> (1 g, 4.24 mmol) and *n*-butylamine (0.56 g, 7.63 mmol) according to the general procedure. Purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a colorless solid (0.99 g, 92% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.74 – 8.68 (m, 1H), 8.55 (dd, *J* = 7.9, 0.5 Hz, 1H), 8.38 (d, *J* = 7.9 Hz, 1H), 8.24 (dd, *J* = 7.7, 0.5 Hz, 1H), 8.16


(s, 1H), 8.01 – 7.95 (m, 1H), 7.89 – 7.83 (m, 1H), 7.38 – 7.34 (m, 1H), 3.56 – 3.52 (m, 2H), 1.72 – 1.63 (m, 2H), 1.52 – 1.42 (m, 2H), 0.99 (t,  $J = 7.4$  Hz, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  164.1, 155.1, 154.6, 149.4, 149.3, 138.3, 136.8, 124.0, 123.5, 122.2, 120.8, 39.2, 31.8, 20.2, 13.8; HRMS (ESI-TOF) calcd for  $\text{C}_{15}\text{H}_{18}\text{N}_3\text{O}^+$   $[\text{M}+\text{H}]^+$ : 256.1444, found: 256.1444.

***N*-methyl-[2,2'-bipyridine]-6-carboxamide (1b)**




Synthesized from **S**<sub>3</sub> (1 g, 4.24 mmol) and methanamine hydrochloride (1.03 g, 7.63 mmol) following general procedure. Purification using preparative TLC (5:1 hexane: ethyl acetate and 5-10%  $\text{Et}_3\text{N}$ ) gave the product as a pale-yellow solid (0.79 g, 87% yield);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.73 – 8.68 (m, 1H), 8.55 (dd,  $J = 7.9, 1.0$  Hz, 1H), 8.40 (d,  $J = 7.9$  Hz, 1H), 8.24 (dd,  $J = 7.6, 1.0$  Hz, 1H), 8.14 (s, 1H), 8.00 – 7.94 (m, 1H), 7.87 – 7.82 (m, 1H), 7.37 – 7.32 (m, 1H), 3.10 (d,  $J = 5.0$ , 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  164.9, 155.1, 154.6, 149.3, 149.3, 138.3, 136.8, 124.1, 123.5, 122.1, 120.9, 26.2; HRMS (ESI-TOF) calcd for  $\text{C}_{12}\text{H}_{11}\text{N}_3\text{NaO}^+$   $[\text{M}+\text{Na}]^+$ : 236.0794, found: 236.0793.

***N*-ethyl-[2,2'-bipyridine]-6-carboxamide (1c)**




Synthesized from **S**<sub>3</sub> (1 g, 4.24 mmol) and ethylamine (0.34 g, 7.63 mmol) following general procedure. Purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10%  $\text{Et}_3\text{N}$ ) gave the product as a colorless solid (0.88 g, 92% yield);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.71 (d,  $J = 4.7$  Hz, 1H), 8.55 (dd,  $J = 7.9, 0.9$  Hz, 1H), 8.39 (d,  $J = 7.9$  Hz, 1H), 8.24 (dd,  $J = 7.7, 0.9$  Hz, 1H), 8.12 (s, 1H), 7.99 (t,  $J = 7.8$  Hz, 1H), 7.82 – 7.90 (m, 1H), 7.39 – 7.33 (m, 1H), 3.63 – 3.52 (m, 2H), 1.33 (t,  $J = 7.3$  Hz, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  164.1, 155.1, 154.6, 149.4, 149.3, 138.3, 136.9, 124.1, 123.5, 122.2, 120.9, 34.3, 15.0; HRMS (ESI-TOF) calcd for  $\text{C}_{13}\text{H}_{14}\text{N}_3\text{O}^+$   $[\text{M}+\text{H}]^+$ : 228.1131, found: 228.1131.

***N*-propyl-[2,2'-bipyridine]-6-carboxamide (1d)**




Synthesized from **S<sub>3</sub>** (1 g, 4.24 mmol) and propan-1-amine (0.45 g, 7.63 mmol) following general procedure. Purification using preparative TLC (8:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N ) gave the product as a colorless solid (0.92 g, 90% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.71 (d, *J* = 4.3 Hz, 1H), 8.58 – 8.47 (m, 1H), 8.38 (d, *J* = 7.9 Hz, 1H), 8.27 – 8.21 (m, 1H), 8.18 (s, 1H), 8.01 – 7.90 (m, 1H), 7.89 – 7.77 (m, 1H), 7.39 – 7.28 (m, 1H), 3.54 – 3.43 (m, 2H), 1.77 – 1.62 (m, 2H), 1.06 – 0.95 (m, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.1, 155.0, 154.5, 149.4, 149.2, 138.2, 136.8, 124.0, 123.4, 122.1, 120.8, 41.1, 23.0, 11.5; HRMS (ESI-TOF) calcd for C<sub>14</sub>H<sub>15</sub>N<sub>3</sub>NaO<sup>+</sup> [M+Na]<sup>+</sup>: 264.1107, found: 264.1110.

#### ***N*-isopropyl-[2,2'-bipyridine]-6-carboxamide (1e)**



Synthesized from **S<sub>3</sub>** (1 g, 4.24 mmol) and isopropylamine (0.45 g, 7.63 mmol) following general procedure. Purification using preparative TLC (4:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a colorless solid (0.91 g, 89% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.72 – 8.70 (m, 1H), 8.55 (d, *J* = 7.9 Hz, 1H), 8.38 (d, *J* = 7.9 Hz, 1H), 8.24 (d, *J* = 7.6 Hz, 1H), 7.99 (d, *J* = 7.8 Hz, 1H), 7.95 (d, *J* = 7.5 Hz, 1H), 7.89 – 7.85 (m, 1H), 7.38 – 7.35 (m, 1H), 4.37 – 4.31 (m, 1H), 1.35 (d, *J* = 6.6 Hz, 6H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.3, 155.1, 154.6, 149.5, 149.3, 138.3, 136.9, 124.1, 123.5, 122.2, 120.9, 41.4, 22.8; HRMS (ESI-TOF) calcd for C<sub>14</sub>H<sub>15</sub>N<sub>3</sub>NaO<sup>+</sup> [M+Na]<sup>+</sup>: 264.1107, found: 264.1110.


#### ***N*-(tert-butyl)-[2,2'-bipyridine]-6-carboxamide (1f)**



Synthesized from **S<sub>3</sub>** (1 g, 4.24 mmol) and tert-butylamine (0.56 g, 7.63 mmol) following general procedure. Purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the


product as a off-white solid (1.06 g, 98% yield);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.70 (d,  $J = 2.3$  Hz, 1H), 8.56 – 8.53 (m, 1H), 8.34 (dd,  $J = 7.9, 2.3$  Hz, 1H), 8.23 – 8.20 (m, 1H), 8.11 (s, 1H), 7.99 – 7.95 (m, 1H), 7.88 – 7.84 (m, 1H), 7.35 (dd,  $J = 5.5, 1.9$  Hz, 1H), 1.55 (d,  $J = 1.8$  Hz, 9H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  163.3, 155.2, 154.4, 150.1, 149.3, 138.3, 136.9, 124.0, 123.3, 121.7, 120.7, 50.9, 28.8; HRMS (ESI-TOF) calcd for  $\text{C}_{15}\text{H}_{17}\text{N}_3\text{NaO}^+$   $[\text{M}+\text{Na}]^+$ : 278.1264, found: 278.1264.

#### ***N*-cyclohexyl-[2,2'-bipyridine]-6-carboxamide (1g)**




Synthesized from **S<sub>3</sub>** (1 g, .24 mmol) and cyclohexylamine (0.76 g, 7.63 mmol) following general procedure. Purification using preparative TLC (8:1 hexane: ethyl acetate and 5-10%  $\text{Et}_3\text{N}$ ) gave the product as a white solid (1.17 g, 98% yield);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.73 – 8.69 (m, 1H), 8.55 (dd,  $J = 7.9, 1.0$  Hz, 1H), 8.37 (d,  $J = 7.9$  Hz, 1H), 8.24 (dd,  $J = 7.7, 1.0$  Hz, 1H), 8.04 (d,  $J = 7.9$  Hz, 1H), 7.98 (t,  $J = 7.8$  Hz, 1H), 7.84–7.90 (m, 1H), 7.34 – 7.40 (m, 1H), 3.97 – 4.08 (m, 1H), 2.07 (dd,  $J = 12.2, 3.2$  Hz, 2H), 1.85 – 1.77 (m, 2H), 1.72 – 1.64 (m, 1H), 1.53 – 1.43 (m, 2H), 1.43 – 1.34 (m, 2H), 1.32 – 1.23 (m, 1H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  163.2, 155.2, 154.6, 149.6, 149.3, 138.3, 136.9, 124.1, 123.4, 122.3, 120.8, 48.1, 33.1, 25.6, 24.9; HRMS (ESI-TOF) calcd for  $\text{C}_{17}\text{H}_{19}\text{N}_3\text{NaO}^+$   $[\text{M}+\text{Na}]^+$ : 304.1420, found: 304.1420.

#### ***N*-phenyl-[2,2'-bipyridine]-6-carboxamide (1h)**




Synthesized from **S<sub>3</sub>** (1 g, 4.24mmol) and aniline (0.71 g, 7.63 mmol) following general procedure. Purification using preparative TLC (2:1 hexane: ethyl acetate and 5-10%  $\text{Et}_3\text{N}$ ) gave the product as a white solid (0.99 g, 85% yield);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  10.07 (s, 1H), 8.76 – 8.70 (m, 1H), 8.61 (dd,  $J = 7.9, 0.8$  Hz, 1H), 8.42 (dd,  $J = 7.9, 0.9$  Hz, 1H), 8.33 (d,  $J = 7.7$  Hz, 1H), 8.00 – 8.07 (m, 1H), 7.93 – 7.87 (m, 1H), 7.84 – 7.80 (m, 2H), 7.42 (t,  $J = 7.9$  Hz, 2H), 7.40 – 7.36 (m, 1H), 7.17 (t,  $J = 7.4$  Hz, 1H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  161.9, 154.8, 154.7, 149.4, 149.1, 138.7, 137.6, 137.0, 129.1, 124.4, 124.2, 124.0, 122.4, 120.9, 119.8; HRMS (ESI-TOF) calcd for  $\text{C}_{17}\text{H}_{13}\text{N}_3\text{NaO}^+$   $[\text{M}+\text{Na}]^+$ : 298.0951, found: 298.0951.

### *N,N*-dimethyl-[2,2'-bipyridine]-6-carboxamide (**1i**)




Synthesized from **S<sub>3</sub>** (1 g, 4.24 mmol) and dimethylamine (0.34 g, 7.63 mmol) following general procedure. Purification using preparative TLC (4:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a creamy white solid (0.84 g, 87% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.68 (d, *J* = 1.7 Hz, 1H), 8.49 – 8.43 (m, 1H), 8.43 – 8.38 (m, 1H), 7.95 – 7.88 (m, 1H), 7.85 – 7.78 (m, 1H), 7.70 – 7.64 (m, 1H), 7.29 – 7.35 (m, 1H), 3.21 – 3.16 (m, 6H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 168.8, 155.5, 154.5, 153.7, 149.1, 137.9, 136.9, 123.9, 123.6, 121.5, 121.2, 39.2, 35.9; HRMS (ESI-TOF) calcd for C<sub>13</sub>H<sub>14</sub>N<sub>3</sub>O<sup>+</sup> [M+H]<sup>+</sup>: 228.1131, found: 228.1131.

### *N*-butyl-6-phenylpicolinamide(**1n**)




Synthesized from 6-phenylpicolinic acid (0.3 g, 1.51 mmol) and *n*-butylamine (0.2 g, 2.71 mmol) following general procedure. Purification using preparative TLC (20:1 hexane: ethyl acetate ) gave the product as a creamy white oil (0.245g, 64% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.21 (t, *J* = 6.1 Hz, 1H), 8.16 (m, *J* = 7.6, 1.1 Hz, 1H), 8.03 – 7.97 (m, 2H), 7.90 (t, *J* = 7.7 Hz, 1H), 7.84 (m, *J* = 7.9, 1.1 Hz, 1H), 7.54 – 7.48 (m, 2H), 7.48 – 7.43 (m, 1H), 3.52 (m, *J* = 7.3, 6.1 Hz, 2H), 1.71 – 1.61 (m, 2H), 1.45 (m, *J* = 14.7, 7.4 Hz, 2H), 0.98 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.3, 155.8, 149.8, 138.4, 138.1, 129.4, 128.8, 126.9, 122.8, 120.5, 39.2, 31.8, 20.2, 13.8; HRMS (ESI-TOF) calcd for C<sub>16</sub>H<sub>18</sub>N<sub>2</sub>O<sup>+</sup> [M+Na]<sup>+</sup>: 277.1311, found: 277.1314.

## 2.3 Procedure for Synthesis of 3a-3h




To a dried 10 mL Schlenk tube equipped with a magnetic stir bar were added 2,2'-bipyridin-6-carboxamide (0.2 mmol), iodobenzene (0.6 mmol, 122.4 mg), Pd(OAc)<sub>2</sub> (0.02 mmol, 4.4 mg), Cs<sub>2</sub>CO<sub>3</sub> (0.8 mmol, 260.6 mg), mesitylene (2 mL). Then the tube was evacuated and back filled with nitrogen (10 times). The mixtures were stirred at 16 °C under a blanket of nitrogen. After 24 hours, the reaction was cooled to room temperature; the crude reaction mixture was diluted with DCM, washed with H<sub>2</sub>O and brine, dried over MgSO<sub>4</sub>. The organic phase was concentrated and purified, running through a silica flash column chromatography to give pure product.

### ***N*-butyl-3'-phenyl-[2,2'-bipyridine]-6-carboxamide (3a)**



**3a** was prepared from **1a** (0.2 mmol, 51.0 mg) and iodobenzene (0.6 mmol, 122.4 mg) according to the general procedure. After 24 hours, and purification using preparative TLC (8:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a colorless solid (53.6 mg, 81% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.73 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.16 (dd, *J* = 7.8, 1.0 Hz, 1H), 8.04 (dd, *J* = 7.7, 1.0 Hz, 1H), 7.91 (t, *J* = 7.8 Hz, 1H), 7.78 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.43 (dd, *J* = 7.7, 4.7 Hz, 1H), 7.35 – 7.29 (m, 3H), 7.22 – 7.16 (m, 2H), 6.80 (s, 1H), 3.20 – 3.13 (m, 2H), 1.44 – 1.37 (m, 2H), 1.33 – 1.25 (m, 2H), 0.93 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.9, 155.9, 153.9, 148.4, 148.2, 141.0, 139.3, 137.9, 137.0, 128.7, 128.3, 126.8, 126.3, 123.3, 121.1, 38.7, 31.6, 20.0, 13.8; HRMS (ESI-TOF) calcd for C<sub>21</sub>H<sub>22</sub>N<sub>3</sub>O<sup>+</sup> [M+H]<sup>+</sup>: 332.1757, found: 332.1758.

### ***N*-methyl-3'-phenyl-[2,2'-bipyridine]-6-carboxamide (3b)**




**3b** was prepared from **1b** (0.2 mmol, 42.6 mg) and iodobenzene (0.6 mmol, 122.4 mg) according to the general procedure. After 24 hours, and purification using preparative TLC (8:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a colorless solid (32.9 mg, 57% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.75 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.21 – 8.19 (m, 1H), 8.03 (dd, *J* = 7.7, 1.0 Hz, 1H), 7.90 (t, *J* = 7.8 Hz, 1H), 7.78 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.45 – 7.41 (m, 1H), 7.37 – 7.32 (m, 3H), 7.22 – 7.17 (m, 2H), 6.62 (s, 1H),




2.72 (d,  $J = 5.1$  Hz, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  164.6, 155.7, 153.5, 148.3, 148.2, 141.4, 139.4, 138.0, 137.1, 128.8, 128.3, 126.7, 126.2, 123.4, 121.0, 25.6; HRMS (ESI-TOF) calcd for  $\text{C}_{18}\text{H}_{16}\text{N}_3\text{O}$   $[\text{M}+\text{H}]^+$ : 290.1288, found: 290.1287.

### ***N*-ethyl-3'-phenyl-[2,2'-bipyridine]-6-carboxamide (3c)**




**3c** was prepared from **1c** (0.2 mmol, 45.4 mg) and iodobenzene (0.6 mmol, 122.4 mg) according to the general procedure. After 24 hours, and purification using preparative TLC (2:1:20 acetone: DCM: hexanes) gave the product as a off-white solid (41.2 mg, 68% yield);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.72 (dd,  $J = 4.7, 1.7$  Hz, 1H), 8.16 (dd,  $J = 7.8, 1.0$  Hz, 1H), 8.04 (dd,  $J = 7.7, 1.0$  Hz, 1H), 7.90 (t,  $J = 7.8$  Hz, 1H), 7.77 (dd,  $J = 7.7, 1.7$  Hz, 1H), 7.42 (dd,  $J = 7.7, 4.7$  Hz, 1H), 7.34 – 7.29 (m, 3H), 7.20 – 7.18 (m, 2H), 6.80 (s, 1H), 3.25 – 3.17 (m, 2H), 1.07 (t,  $J = 7.3$  Hz, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  163.8, 155.9, 153.7, 148.3, 148.2, 141.0, 139.3, 137.9, 137.0, 128.7, 128.2, 126.8, 126.3, 123.3, 121.0, 33.8, 14.7; HRMS (ESI-TOF) calcd for  $\text{C}_{19}\text{H}_{18}\text{N}_3\text{O}^+$   $[\text{M}+\text{H}]^+$ : 304.1444, found: 304.1444.

### **3'-phenyl-*N*-propyl-[2,2'-bipyridine]-6-carboxamide (3d)**




**3d** was prepared from **1d** (0.2 mmol, 48.2 mg) and iodobenzene (0.6 mmol, 122.4 mg) according to the general procedure. After 24 hours, and purification using preparative TLC (8:1 hexane: ethyl acetate and 5-10%  $\text{Et}_3\text{N}$ ) gave the product as a yellow solid (37.4 mg, 59% yield);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.72 (dd,  $J = 4.7, 1.6$  Hz, 1H), 8.17 – 8.14 (m, 1H), 8.04 (d,  $J = 7.6$  Hz, 1H), 7.90 (t,  $J = 7.8$  Hz, 1H), 7.77 (dd,  $J = 7.7, 1.6$  Hz, 1H), 7.42 (dd,  $J = 7.7, 4.7$  Hz, 1H), 7.33 – 7.29 (m, 3H), 7.18 (dd,  $J = 7.6, 1.7$  Hz, 2H), 6.84 (s, 1H), 3.15 – 3.11 (m, 2H), 1.47 – 1.42 (m, 2H), 0.87 (t,  $J = 7.4$  Hz, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  164.0, 155.9, 153.8, 148.4, 148.2, 140.9, 139.3, 137.9, 137.0, 128.7, 128.3, 126.8, 126.3, 123.3, 121.1, 40.7, 22.8, 11.4; HRMS (ESI-TOF) calcd for  $\text{C}_{20}\text{H}_{19}\text{N}_3\text{NaO}^+$   $[\text{M}+\text{Na}]^+$ : 340.1420, found: 340.1420.

### ***N*-isopropyl-3'-phenyl-[2,2'-bipyridine]-6-carboxamide (3e)**




**3e** was prepared from **1e** (0.2 mmol, 48.2 mg) and iodobenzene (0.6 mmol, 122.4 mg) according to the general procedure. After 24 hours, and purification using preparative TLC (8:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N ) gave the product as a pale-yellow (38.2 mg, 60% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.72 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.10 (dd, *J* = 7.8, 1.1 Hz, 1H), 8.06 (dd, *J* = 7.7, 1.1 Hz, 1H), 7.91 (t, *J* = 7.8 Hz, 1H), 7.79 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.44 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.33 – 7.28 (m, 3H), 7.18 – 7.15 (m, 2H), 6.83 (d, *J* = 8.0 Hz, 1H), 4.09 – 4.00 (m, 1H), 1.07 (d, *J* = 6.6 Hz, 6H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.1, 156.2, 154.2, 148.5, 148.1, 140.6, 139.2, 137.9, 137.0, 128.8, 128.4, 127.2, 126.5, 123.4, 121.1, 41.0, 22.5; HRMS (ESI-TOF) calcd for C<sub>20</sub>H<sub>20</sub>N<sub>3</sub>O<sup>+</sup> [M+H]<sup>+</sup>: 318.1601, found: 318.1601.

***N*-(tert-butyl)-3'-phenyl-[2,2'-bipyridine]-6-carboxamide (3f)**




**3f** was prepared from **1f** (0.2 mmol, 51.0 mg) and iodobenzene (0.2 mmol, 122.4 mg) according to the general procedure. After 24 hours, purification using preparative TLC (5:4:1 hexane : DCM : EA) gave the product as a white solid (29.8 mg, 45% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.72 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.06 (dd, *J* = 7.7, 1.1 Hz, 1H), 8.02 (dd, *J* = 7.8, 1.1 Hz, 1H), 7.91 (t, *J* = 7.8 Hz, 1H), 7.81 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.45 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.30 – 7.27 (m, 3H), 7.17 – 7.10 (m, 3H), 1.29 (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.1, 156.2, 154.6, 149.2, 148.1, 140.2, 139.1, 138.0, 137.1, 128.9, 128.5, 127.0, 126.5, 123.4, 120.6, 50.6, 28.5; HRMS (ESI-TOF) calcd for C<sub>21</sub>H<sub>22</sub>N<sub>3</sub>O<sup>+</sup> [M+H]<sup>+</sup>: 332.1757, found: 332.1757.

***N*-cyclohexyl-3'-phenyl-[2,2'-bipyridine]-6-carboxamide (3g)**




**3g** was prepared from **1g** (0.2 mmol, 56.2 mg) and iodobenzene (0.6 mmol, 122.4 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane : EA and 5-10% Et<sub>3</sub>N) gave the product as a white solid (52.8 mg, 74% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.71 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.08 (dd, *J* = 4.1, 1.0 Hz, 1H), 8.06 (d, *J* = 3.2 Hz, 1H), 7.90 (t, *J* = 7.8 Hz, 1H), 7.79 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.43 (dd, *J* = 7.7, 4.7 Hz, 1H), 7.32 – 7.27 (m, 3H), 7.18 – 7.14 (m, 2H), 6.93 (d, *J* = 8.3 Hz, 1H), 3.78 – 3.67 (m, 1H), 1.83 – 1.74 (m, 2H), 1.74 – 1.67 (m, 2H), 1.66 – 1.59 (m, 1H), 1.38 – 1.29 (m, 2H), 1.21 – 1.14 (m, 1H), 1.07 – 1.01 (m, 2H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.0, 156.2, 154.2, 148.6, 148.0, 140.3, 139.1, 137.8, 136.9, 128.7, 128.4, 127.1, 126.5, 123.3, 121.1, 48.0, 32.6, 25.5, 24.8; HRMS (ESI-TOF) calcd for C<sub>23</sub>H<sub>24</sub>N<sub>3</sub>O<sup>+</sup> [M+H]<sup>+</sup>: 358.1914, found: 358.1914.

### ***N*,3'-diphenyl-[2,2'-bipyridine]-6-carboxamide (3h)**



**3h** was prepared from **1h** (0.2 mmol, 55.0 mg) and iodobenzene (0.6 mmol, 22.4 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a white solid (28.8 mg, 41% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.90 (s, 1H), 8.75 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.20 – 8.13 (m, 2H), 7.98 (dd, *J* = 9.7, 5.9 Hz, 1H), 7.84 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.55 – 7.50 (m, 2H), 7.46 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.34 (dd, *J* = 10.8, 5.1 Hz, 2H), 7.31 – 7.27 (m, 2H), 7.25 – 7.20 (m, 2H), 7.19 – 7.14 (m, 1H), 7.13 – 7.08 (m, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 161.7, 156.2, 153.9, 148.2, 148.1, 140.3, 139.2, 138.3, 137.4, 137.0, 128.7, 128.7, 128.5, 127.3, 127.0, 124.0, 123.5, 121.3, 120.0; HRMS (ESI-TOF) calcd for C<sub>23</sub>H<sub>17</sub>N<sub>3</sub>NaO<sup>+</sup> [M+Na]<sup>+</sup>: 374.1264, found: 374.1264.


### **2-(biphenyl-2-yl)pyridine (3m)**



To a dried 10 mL Schlenk tube equipped with a magnetic stir bar were added 2-phenylpyridine (0.2 mmol, 31 mg), iodobenzene (0.6 mmol, 122.4 mg), Pd(OAc)<sub>2</sub> (0.02 mmol, 4.5 mg), Cs<sub>2</sub>CO<sub>3</sub> (0.8 mmol, 260.6 mg), mesitylene (2 mL). Then the tube was evacuated and back filled with nitrogen (10 times). The mixtures were stirred at 160 °C under a blanket of nitrogen. After 24 hours, the reaction was cooled to room temperature; the crude reaction mixture was diluted with DCM, washed with H<sub>2</sub>O and brine, dried


over  $\text{Mg}_2\text{SO}_4$ . The organic phase was concentrated and purification using preparative TLC (15:1 hexane: ethyl acetate) gave the product as a colorless solid (6 mg, 13% yield).  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.64-8.62 (m, 1H), 7.71 – 7.69 (m, 1H), 7.48 – 7.43 (m, 3H), 7.39-7.36 (m, 1H), 7.24 – 7.22 (m, 3H), 7.17 – 7.15 (m, 2H), 7.11-7.08 (m, 1H), 6.88 (dd,  $J = 7.9, 0.9$  Hz, 1H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  159.2, 149.4, 141.3, 140.6, 139.4, 135.2, 130.5, 130.4, 129.7, 128.5, 128.0, 127.6, 126.7, 125.4, 121.3.

## 2.4 Procedure for Synthesis of 4a-4v




To a dried 10 mL Schlenk tube equipped with a magnetic stir bar were added *N*-butyl-[2,2'-bipyridine]-6-carboxamide (0.2 mmol, 51.0 mg), iodobenzene (0.6 mmol),  $\text{Pd(OAc)}_2$  (0.02 mmol, 4.4 mg),  $\text{Cs}_2\text{CO}_3$  (0.8 mmol, 260.6 mg), mesitylene (2 mL). Then the tube was evacuated and back filled with nitrogen (10 times). The mixtures were stirred at 160 °C under a blanket of nitrogen. After 24-48 hours, the reaction was cooled to room temperature. The crude reaction mixture was diluted with DCM, washed with  $\text{H}_2\text{O}$  and brine, dried over  $\text{Mg}_2\text{SO}_4$ . The organic phase was concentrated and purified, running through a silica flash column chromatography (ethyl acetate / hexane and 5-10%  $\text{Et}_3\text{N}$ ) to give pure product.

### *N*-butyl-3'-(*p*-tolyl)-[2,2'-bipyridine]-6-carboxamide (4a)




**4a** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-iodo-4-methylbenzene (0.6 mmol, 130.8 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane:ethyl acetate and 5-10%  $\text{Et}_3\text{N}$ ) gave the product as a yellow oil (57.3 mg, 82% yield);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.70 (dd,  $J = 4.7, 1.5$  Hz, 1H), 8.16 – 8.11 (m, 1H), 8.04 (d,  $J = 7.1$  Hz, 1H), 7.90 (t,  $J = 7.8$  Hz, 1H), 7.76 (dd,  $J = 7.7, 1.6$  Hz, 1H), 7.41 (dd,  $J = 7.7, 4.7$  Hz, 1H), 7.12 (d,  $J = 7.9$  Hz, 2H), 7.06 (d,  $J = 8.0$  Hz, 2H), 6.92 (d,  $J = 5.2$  Hz, 1H), 3.21 – 3.14 (m, 2H), 2.35 (s, 3H), 1.44 – 1.37 (m, 2H), 1.33 – 1.24 (m, 2H), 0.94 (t,  $J = 7.3$  Hz, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  163.9, 156.0, 153.8, 148.3, 147.9, 139.2, 137.9, 137.8, 136.9, 136.4, 128.9, 128.5, 126.2, 123.3, 120.9, 38.7, 31.6, 21.0, 20.0, 13.7; HRMS (ESI-TOF) calcd for  $\text{C}_{22}\text{H}_{24}\text{N}_3\text{O}^+ [\text{M}+\text{H}]^+$ : 346.1914. found: 346.1914.

***N*-butyl-3'-(4-(tert-butyl)phenyl)-[2,2'-bipyridine]-6-carboxamide (4b)**




**4b** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-(tert-butyl)-4-iodobenzene (0.6 mmol, 156.1 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane:ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a yellow oil (61.9 mg, 80% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.71 (dd, *J* = 4.7, 1.3 Hz, 1H), 8.05 (d, *J* = 3.3 Hz, 1H), 8.03 (d, *J* = 3.5 Hz, 1H), 7.90 (t, *J* = 7.8 Hz, 1H), 7.79 (dd, *J* = 7.7, 1.3 Hz, 1H), 7.42 (dd, *J* = 7.7, 4.8 Hz, 1H), 7.31 (d, *J* = 8.3 Hz, 2H), 7.09 (d, *J* = 8.3 Hz, 3H), 3.21 – 3.15 (m, 2H), 1.46 – 1.40 (m, 2H), 1.32 – 1.26 (m, 11H), 0.92 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.0, 156.3, 154.4, 150.0, 148.4, 148.0, 139.2, 137.9, 137.6, 137.0, 128.4, 126.4, 125.2, 123.3, 120.9, 38.9, 34.5, 31.5, 31.3, 20.1, 13.8; HRMS (ESI-TOF) calcd for C<sub>25</sub>H<sub>30</sub>N<sub>3</sub>O<sup>+</sup> [M+H]<sup>+</sup>: 388.2383, found: 388.2387.

***N*-butyl-3'-(4-methoxyphenyl)-[2,2'-bipyridine]-6-carboxamide (4c)**




**4c** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-iodo-4-methoxybenzene (0.6 mmol, 140.4 mg) according to the general procedure. After 24 hours, purification using preparative TLC (4:1 hexane : ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a cream oil (39.7 mg, 55% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.70 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.09 (dd, *J* = 7.8, 1.1 Hz, 1H), 8.05 (dd, *J* = 7.7, 1.1 Hz, 1H), 7.90 (t, *J* = 7.8 Hz, 1H), 7.76 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.41 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.11 – 7.07 (m, 2H), 7.01 (t, *J* = 5.5 Hz, 1H), 6.86 – 6.83 (m, 2H), 3.79 (s, 3H), 3.23 – 3.20 (m, 2H), 1.45 – 1.39 (m, 2H), 1.35 – 1.29 (m, 2H), 0.94 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.0, 158.7, 156.2, 153.9, 148.5, 147.9, 139.2, 137.9, 136.7, 133.0, 130.0, 126.4, 123.3, 121.0, 113.7, 55.1, 38.8, 31.4, 20.1, 13.7; HRMS (ESI-TOF) calcd for C<sub>22</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M+H]<sup>+</sup>: 362.1863, found: 362.1863.

**3'-(4-bromophenyl)-*N*-butyl-[2,2'-bipyridine]-6-carboxamide (4d)**




**4d** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-bromo-4-iodobenzene (0.6 mmol, 169.7 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane:ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a cream solid (69.7 mg, 85% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.79 – 8.71 (m, 1H), 8.22 (t, *J* = 7.2 Hz, 1H), 8.15 – 8.03 (m, 1H), 8.00 – 7.88 (m, 1H), 7.80 – 7.68 (m, 1H), 7.52 – 7.40 (m, 3H), 7.08 (dd, *J* = 13.5, 5.1 Hz, 2H), 6.82 (s, 1H), 3.31 – 3.18 (m, 2H), 1.50 – 1.41 (m, 2H), 1.38 – 1.30 (m, 2H), 1.00 – 1.93 (m, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.7, 155.6, 153.5, 148.5, 148.3, 140.0, 139.1, 138.1, 135.7, 131.4, 130.3, 126.3, 123.4, 121.3, 121.1, 38.9, 31.7, 20.1, 13.8; HRMS (ESI-TOF) calcd for C<sub>21</sub>H<sub>20</sub>BrN<sub>3</sub>NaO<sup>+</sup> [M+Na]<sup>+</sup>: 432.0682, found: 432.0682.

***N*-butyl-3'-(4-iodophenyl)-[2,2'-bipyridine]-6-carboxamide (4e)**




**4e** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1,4-diiodobenzene (0.6 mmol, 197.9 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane:ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a cream solid (33.8 mg, 37% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.74 (dd, *J* = 4.7, 1.5 Hz, 1H), 8.21 (d, *J* = 7.8 Hz, 1H), 8.08 (d, *J* = 7.7 Hz, 1H), 7.93 (t, *J* = 7.8 Hz, 1H), 7.73 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.66 (d, *J* = 8.3 Hz, 2H), 7.43 (dd, *J* = 7.7, 4.7 Hz, 1H), 6.94 (d, *J* = 8.3 Hz, 2H), 6.82 (s, 1H), 3.29 – 3.21 (m, 2H), 1.49 – 1.42 (m, 2H), 1.39 – 1.31 (m, 2H), 0.97 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.8, 155.6, 153.6, 148.6, 148.4, 140.7, 139.2, 138.2, 137.5, 135.9, 130.6, 126.4, 123.5, 121.4, 92.6, 39.0, 31.9, 20.2, 13.9; HRMS (ESI-TOF) calcd for C<sub>21</sub>H<sub>20</sub>IN<sub>3</sub>KO<sup>+</sup> [M+K]<sup>+</sup>: 496.0283, found: 496.0283.

***N*-butyl-3'-(4-(trifluoromethoxy)phenyl)-[2,2'-bipyridine]-6-carboxamide (4f)**




**4f** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-iodo-4-(trifluoromethoxy)benzene (0.6 mmol, 172.8 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a cream solid (63.9 mg, 77% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.75 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.14 (dd, *J* = 7.8, 1.0 Hz, 1H), 8.08 (dd, *J* = 7.7, 1.0 Hz, 1H), 7.93 (t, *J* = 7.8 Hz, 1H), 7.77 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.45 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.23 – 7.19 (m, 2H), 7.17 (d, *J* = 8.6 Hz, 2H), 6.94 (t, *J* = 5.5 Hz, 1H), 3.22 – 3.18 (m, 2H), 1.45 – 1.38 (m, 2H), 1.33 – 1.28 (m, 2H), 0.93 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.7, 155.7, 154.0, 148.6, 148.5, 148.27 (q, *J* = 1.9 Hz), 139.4, 139.2, 138.121, 135.6, 130.1, 126.5, 123.4, 121.3, 120.6, 120.4 (q, *J* = 257.7 Hz), 38.8, 31.6, 20.1, 13.6; HRMS (ESI-TOF) calcd for C<sub>22</sub>H<sub>21</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M+H]<sup>+</sup>: 416.1580 found: 416.1580.

**ethyl 4-(6'-(butylcarbamoyl)-[2,2'-bipyridin]-3-yl)benzoate (4g)**




**4g** was prepared from **1a** (0.2 mmol, 51.0 mg) and ethyl 4-iodobenzoate (0.6 mmol, 165.6 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a colorless solid (70.1 mg, 87% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.76 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.23 (dd, *J* = 7.8, 1.0 Hz, 1H), 8.06 (dd, *J* = 7.7, 1.0 Hz, 1H), 8.04 – 7.99 (m, 2H), 7.94 (t, *J* = 7.8 Hz, 1H), 7.78 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.46 (dd, *J* = 7.7, 4.7 Hz, 1H), 7.29 – 7.26 (m, 2H), 6.71 (t, *J* = 5.5 Hz, 1H), 4.42 – 4.36 (m, 2H), 3.13 – 3.09 (m, 2H), 1.40 (t, *J* = 7.1 Hz, 3H), 1.37 – 1.32 (m, 2H), 1.30 – 1.24 (m, 2H), 0.92 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.0, 163.7, 155.5, 153.8, 148.7, 148.3, 145.8, 139.1, 138.2, 136.1, 129.6, 129.0, 128.7, 126.3, 123.4, 121.4, 61.1, 38.7, 31.6, 20.0, 14.3, 13.7; HRMS (ESI-TOF) calcd for C<sub>24</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M+H]<sup>+</sup>: 404.1969, found: 404.1969.

**N-butyl-3'-(4-formylphenyl)-[2,2'-bipyridine]-6-carboxamide (4h)**



**4h** was prepared from **1a** (0.2 mmol, 51.0 mg) and 4-iodobenzaldehyde (0.6 mmol, 139.2 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a yellow oil (65.3 mg, 91% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.02 (s, 1H), 8.78 (dd, *J* = 4.7, 1.5 Hz, 1H), 8.23 (dd, *J* = 7.8, 0.9 Hz, 1H), 8.08 (d, *J* = 7.7 Hz, 1H), 7.95 (t, *J* = 7.8 Hz, 1H), 7.86 (d, *J* = 8.1 Hz, 2H), 7.80 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.49 (dd, *J* = 7.7, 4.7 Hz, 1H), 7.38 (d, *J* = 8.1 Hz, 2H), 6.75 (t, *J* = 5.5 Hz, 1H), 3.12 – 3.07 (m, 2H), 1.35 – 1.30 (m, 2H), 1.27 – 1.22 (m, 2H), 0.91 (t, *J* = 7.2 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 191.2, 163.6, 155.3, 153.7, 148.9, 148.3, 147.4, 139.0, 138.2, 135.6, 134.7, 129.6, 129.4, 126.4, 123.4, 121.4, 38.7, 31.6, 19.9, 13.6; HRMS (ESI-TOF) calcd for C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>NaO<sub>2</sub><sup>+</sup> [M+Na]<sup>+</sup>: 382.1526, found: 382.1526.


### 3'-(4-acetylphenyl)-*N*-butyl-[2,2'-bipyridine]-6-carboxamide (**4i**)



**4i** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-(4-iodophenyl)ethanone (0.6 mmol, 147.6 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a white solid (56.0 mg, 75% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.77 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.21 (dd, *J* = 7.8, 1.1 Hz, 1H), 8.07 (dd, *J* = 7.7, 1.1 Hz, 1H), 7.96 – 7.92 (m, 3H), 7.78 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.47 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.32 – 7.29 (m, 2H), 6.77 (t, *J* = 5.7 Hz, 1H), 3.13 – 3.06 (m, 2H), 2.60 (s, 3H), 1.36 – 1.30 (m, 2H), 1.28 – 1.22 (m, 2H), 0.91 (t, *J* = 7.2 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 197.1, 163.7, 155.5, 153.8, 148.8, 148.4, 146.0, 139.1, 138.2, 135.9, 135.4, 129.0, 128.4, 126.4, 123.4, 121.4, 38.8, 31.7, 26.5, 20.0, 13.7; HRMS (ESI-TOF) calcd for C<sub>23</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M+H]<sup>+</sup>: 374.1863, found: 374.1863.


### *N*-butyl-3'-(4-cyanophenyl)-[2,2'-bipyridine]-6-carboxamide (**4j**)






**4j** was prepared from **1a** (0.2 mmol, 51.0 mg) and 4-iodobenzonitrile (0.6 mmol, 137.4 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a white solid (58.4 mg, 82% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.79 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.22 (dd, *J* = 7.8, 0.9 Hz, 1H), 8.11 (dd, *J* = 7.7, 1.0 Hz, 1H), 7.96 (t, *J* = 7.8 Hz, 1H), 7.76 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.65 – 7.61 (m, 2H), 7.49 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.33 – 7.30 (m, 2H), 6.76 (s, 1H), 3.24 – 3.19 (m, 2H), 1.45 – 1.38 (m, 2H), 1.34 – 1.30 (m, 2H), 0.96 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.6, 155.2, 153.8, 149.2, 148.4, 146.0, 139.0, 138.4, 135.1, 132.1, 130.0, 126.5, 123.5, 121.7, 118.3, 110.9, 38.9, 31.8, 20.1, 13.8; HRMS (ESI-TOF) calcd for C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>NaO<sup>+</sup> [M+Na]<sup>+</sup>: 379.1529, found: 379.1529.

***N*-butyl-3'-(4-nitrophenyl)-[2,2'-bipyridine]-6-carboxamide (4k)**




**4k** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-iodo-4-nitrobenzene (0.6 mmol, 149.4 mg) according to the general procedure. After 24 hours, purification using preparative TLC (4:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a colorless solid (60.9 mg, 81% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.81 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.25 (dd, *J* = 7.8, 1.0 Hz, 1H), 8.23 – 8.19 (m, 2H), 8.10 (dd, *J* = 7.7, 1.0 Hz, 1H), 7.97 (t, *J* = 7.8 Hz, 1H), 7.79 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.50 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.40 – 7.35 (m, 2H), 6.75 (s, 1H), 3.15 – 3.10 (m, 2H), 1.35 – 1.29 (m, 2H), 1.27 – 1.21 (m, 2H), 0.91 (t, *J* = 7.2 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.5, 155.2, 153.9, 149.3, 148.4, 148.0, 146.7, 139.0, 138.4, 134.7, 129.6, 126.5, 123.6, 123.5, 121.7, 38.8, 31.7, 20.0, 13.6; HRMS(ESI-TOF) calcd for C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>NaO<sub>3</sub><sup>+</sup> [M+Na]<sup>+</sup>: 399.1428, found: 399.1428.

***N*-butyl-3'-(3-methoxyphenyl)-[2,2'-bipyridine]-6-carboxamide (4l)**




**4l** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-iodo-3-methoxybenzene (0.6 mmol, 140.4 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a white solid (60.7 mg, 84% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.76 – 8.66 (m, 1H), 8.14 (dd, *J* = 7.8, 1.2 Hz, 1H), 8.08 – 7.99 (m, 1H), 7.94 – 7.85 (m, 1H), 7.81 – 7.72 (m, 1H), 7.45 – 7.36 (m, 1H), 7.25 – 7.16 (m, 1H), 6.93 (s, 1H), 6.86 – 6.78 (m, 1H), 6.73 (d, *J* = 11.5 Hz, 2H), 3.71 – 3.65 (m, 3H), 3.22 – 3.14 (m, 2H), 1.46 – 1.37 (m, 2H), 1.32 – 1.24 (m, 2H), 0.93 (t, *J* = 7.0 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.0, 159.5, 155.9, 153.9, 148.4, 148.3, 142.4, 139.2, 137.9, 136.9, 129.3, 126.2, 123.3, 121.2, 121.1, 114.3, 112.3, 55.1, 38.9, 31.6, 20.1, 13.8; HRMS (ESI-TOF) calcd for C<sub>22</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M+H]<sup>+</sup>: 362.1863, found: 362.1863.

***N*-butyl-3'-(3-fluorophenyl)-[2,2'-bipyridine]-6-carboxamide (4m)**




**4m** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-fluoro-3-iodobenzene (0.6 mmol, 133.2 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a colorless solid (54.4 mg, 78% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.76 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.20 (dd, *J* = 7.8, 0.9 Hz, 1H), 8.09 (dd, *J* = 7.7, 0.9 Hz, 1H), 7.95 (t, *J* = 7.8 Hz, 1H), 7.78 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.46 (dd, *J* = 7.7, 4.7 Hz, 1H), 7.30 – 7.26 (m, 1H), 7.04 – 6.95 (m, 2H), 6.94 – 6.89 (m, 2H), 3.25 – 3.21 (m, 2H), 1.47 – 1.42 (m, 2H), 1.35 – 1.30 (m, 2H), 0.96 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.7, 162.5 (d, *J* = 246.9 Hz), 155.6, 153.8, 148.5, 148.3, 143.2 (d, *J* = 7.8 Hz), 139.0, 138.0, 135.7 (d, *J* = 1.9 Hz), 129.7 (d, *J* = 8.3 Hz), 126.3, 124.5 (d, *J* = 2.9 Hz), 123.3, 121.2, 115.6 (d, *J* = 21.9 Hz), 113.7 (d, *J* = 20.9 Hz), 38.8, 31.5, 20.0, 13.7; HRMS (ESI-TOF) calcd for C<sub>21</sub>H<sub>21</sub>FN<sub>3</sub>O<sup>+</sup> [M+H]<sup>+</sup>: 350.1663, found: 350.1664.

***N*-butyl-3'-(3-chlorophenyl)-[2,2'-bipyridine]-6-carboxamide(4n)**




**4n** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-chloro-3-iodobenzene (0.6 mmol, 143.1 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a cream solid (64.2 mg, 88% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.75 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.20 (d, *J* = 7.8 Hz, 1H), 8.08 (d, *J* = 7.7 Hz, 1H), 7.94 (t, *J* = 7.8 Hz, 1H), 7.76 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.44 (dd, *J* = 7.7, 4.7 Hz, 1H), 7.34 – 7.27 (m, 2H), 7.20 (t, *J* = 7.8 Hz, 1H), 6.95 (d, *J* = 7.7 Hz, 1H), 6.86 (s, 1H), 3.26 – 3.18 (m, 2H), 1.48 – 1.41 (m, 2H), 1.36 – 1.28 (m, 2H), 0.94 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.8, 155.5, 153.8, 148.7, 148.4, 142.9, 139.2, 138.1, 135.6, 134.3, 129.4, 128.6, 127.1, 127.0, 126.3, 123.4, 121.3, 39.0, 31.7, 20.1, 13.8; HRMS (ESI-TOF) calcd for C<sub>21</sub>H<sub>21</sub>ClN<sub>3</sub>O<sup>+</sup> [M+H]<sup>+</sup>: 366.1368, found: 366.1368.

### 3'-(3-bromophenyl)-*N*-butyl-[2,2'-bipyridine]-6-carboxamide (**4o**)




**4o** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-bromo-3-iodobenzene (0.6 mmol, 169.2 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a cream solid (54.8 mg, 67% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.74 (dd, *J* = 4.7, 1.4 Hz, 1H), 8.21 (d, *J* = 7.7 Hz, 1H), 8.08 (d, *J* = 7.6 Hz, 1H), 7.94 (t, *J* = 7.8 Hz, 1H), 7.75 (dd, *J* = 7.7, 1.4 Hz, 1H), 7.51 – 7.41 (m, 3H), 7.13 (t, *J* = 7.8 Hz, 1H), 6.99 (d, *J* = 7.7 Hz, 1H), 6.85 (s, 1H), 3.26 – 3.17 (m, 2H), 1.49 – 1.41 (m, 2H), 1.36 – 1.28 (m, 2H), 0.95 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.8, 155.5, 153.7, 148.7, 148.3, 143.2, 139.2, 138.1, 135.4, 131.4, 129.9, 129.7, 127.6, 126.3, 123.4, 122.3, 121.3, 39.0, 31.8, 20.1, 13.8; HRMS (ESI-TOF) calcd for C<sub>21</sub>H<sub>20</sub>BrN<sub>3</sub>NaO<sup>+</sup> [M+Na]<sup>+</sup>: 432.0682, found: 432.0682.

### *N*-butyl-3'-(3-(trifluoromethyl)phenyl)-[2,2'-bipyridine]-6-carboxamide (**4p**)




**4p** was prepared from **1a** (0.2mmol, 51.0 mg) and 1-iodo-3-(trifluoromethyl)benzene (0.6 mmol, 163.2 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a yellow oil (33.5 mg, 42% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.77 (dd, *J* = 4.7, 1.3 Hz, 1H), 8.20 (d, *J* = 7.7 Hz, 1H), 8.09 (d, *J* = 7.6 Hz, 1H), 7.95 (t, *J* = 7.8 Hz, 1H), 7.80 (dd, *J* = 7.7, 1.4 Hz, 1H), 7.59 – 7.54 (m, 2H), 7.48 (dd, *J* = 7.7, 4.7 Hz, 1H), 7.40 (t, *J* = 7.7 Hz, 1H), 7.29 (d, *J* = 7.8 Hz, 1H), 6.77 (s, 1H), 3.18 – 3.12 (m, 2H), 1.39 – 1.33 (m, 2H), 1.27 – 1.24 (m, 2H); 0.91 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.7, 155.5, 153.9, 148.8, 148.3, 141.7, 139.2, 138.2, 135.4, 132.3, 130.9 (q, *J* = 32.5 Hz), 128.6, 126.5, 125.4 (q, *J* = 3.7 Hz), 123.8 (q, *J* = 272.3 Hz), 123.6 (q, *J* = 3.6 Hz), 123.5, 121.4, 38.8, 31.6, 20.0, 13.6; HRMS (ESI-TOF) calcd for C<sub>22</sub>H<sub>21</sub>F<sub>3</sub>N<sub>3</sub>O<sup>+</sup> [M+H]<sup>+</sup>: 400.1631, found: 400.1631.

***N*-butyl-3'-(3-nitrophenyl)-[2,2'-bipyridine]-6-carboxamide(4q)**




**4q** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-iodo-3-nitrobenzene (0.6 mmol, 149.4 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate) gave the product as a white solid (48.9 mg, 65% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.80 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.22 (dd, *J* = 7.8, 1.0 Hz, 1H), 8.20 – 8.15 (m, 2H), 8.09 (dd, *J* = 7.7, 1.0 Hz, 1H), 7.97 (t, *J* = 7.8 Hz, 1H), 7.82 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.51 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.48 – 7.40 (m, 2H), 6.81 (s, 1H), 3.19 – 3.11 (m, 2H), 1.35 – 1.28 (m, 2H), 1.27 – 1.20 (m, 2H), 0.90 (t, *J* = 7.2 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.4, 155.2, 153.9, 149.1, 148.2, 148.1, 142.6, 139.0, 138.3, 134.9, 134.4, 129.1, 126.6, 123.5, 123.3, 121.8, 121.5, 38.8, 31.5, 19.9, 13.6.; HRMS (ESI-TOF) calcd for C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>NaO<sub>3</sub><sup>+</sup> [M+Na]<sup>+</sup>: 399.1428, found: 399.1428.

***N*-butyl-3'-(2-methoxyphenyl)-[2,2'-bipyridine]-6-carboxamide (4r)**




**4r** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-iodo-2-methoxybenzene (0.6 mmol, 140.4 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a scream oil (32.5 mg, 45% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.71 (dd, *J* = 4.7, 1.5 Hz, 1H), 8.16 (d, *J* = 7.8 Hz, 1H), 8.04 (dd, *J* = 7.7, 1.0 Hz, 1H), 7.91 (t, *J* = 7.8 Hz, 1H), 7.75 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.43 (dd, *J* = 7.7, 4.8 Hz, 1H), 7.35 (dd, *J* = 7.4, 1.7 Hz, 1H), 7.33 – 7.28 (m, 1H), 7.10 – 7.05 (m, 1H), 6.83 (s, 1H), 6.72 (d, *J* = 8.1 Hz, 1H), 3.32 – 3.00 (m, 5H), 1.45 – 1.37 (m, 2H), 1.34 – 1.26 (m, 2H), 0.93 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.1, 156.9, 155.4, 154.8, 148.0, 139.8, 137.7, 133.3, 130.2, 130.1, 128.9, 125.4, 123.4, 121.0, 120.8, 110.7, 100.0, 54.8, 38.8, 31.7, 20.1, 13.8; HRMS (ESI-TOF) calcd for C<sub>22</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M+H]<sup>+</sup>: 362.1863; found: 362.1863.

***N*-butyl-3'-(2-fluorophenyl)-[2,2'-bipyridine]-6-carboxamide(4s)**




**4s** was prepared from **1a** (0.2 mmol, 51.0 mg) and 1-fluoro-2-iodobenzene (0.6 mmol, 133.2 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10%Et<sub>3</sub>N) gave the product as a white solid (28.6 mg, 41% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.76 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.24 (dd, *J* = 7.9, 0.9 Hz, 1H), 8.07 (dd, *J* = 7.7, 0.9 Hz, 1H), 7.94 (t, *J* = 7.8 Hz, 1H), 7.77 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.45 (dd, *J* = 7.7, 4.7 Hz, 1H), 7.34 – 7.29 (m, 2H), 7.23 – 7.19 (m, 1H), 6.97 (t, *J* = 9.0 Hz, 1H), 6.82 (s, 1H), 3.20 – 3.13 (m, 2H), 1.44 – 1.39 (m, 2H), 1.33 – 1.29 (m, 2H), 0.93 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.0, 159.0 (d, *J* = 246.8 Hz), 156.1, 154.6, 148.8, 148.2, 139.8, 138.1, 130.6 (d, *J* = 2.9 Hz), 129.2 (d, *J* = 8.0 Hz), 128.9 (d, *J* = 15.9 Hz), 125.9, 124.2 (d, *J* = 3.7 Hz), 123.3, 121.4, 115.6 (d, *J* = 22.0 Hz); HRMS (ESI-TOF) calcd for C<sub>21</sub>H<sub>20</sub>FN<sub>3</sub>NaO [M+Na]<sup>+</sup>: 372.1483. found: 372.1482.

**dimethyl 5-(6'-(butylcarbamoyl)-[2,2'-bipyridin]-3-yl)isophthalate (4t)**




**4t** was prepared from **1a** (0.2 mmol, 51.0 mg) and diethyl 5-iodoisophthalate (0.6 mmol, 192.0) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a white solid (42.9 mg, 48% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.82 – 8.76 (m, 1H), 8.63 (d, *J* = 5.4 Hz, 1H), 8.26 (dd, *J* = 7.8, 4.3 Hz, 1H), 8.11 – 8.04 (m, 3H), 8.00 – 7.93 (m, 1H), 7.83 – 7.77 (m, 1H), 7.52 – 7.46 (m, 1H), 6.72 (d, *J* = 5.3 Hz, 1H), 3.92 (d, *J* = 6.1 Hz, 6H), 3.14 – 3.07 (m, 2H), 1.31 – 1.26 (m, 2H), 1.25 – 1.18 (m, 2H), 0.90 (t, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 165.6, 163.6, 155.3, 153.9, 149.0, 148.2, 142.0, 139.2, 138.3, 134.9, 133.8, 130.8, 129.0, 126.6, 123.5, 121.5, 52.5, 38.8, 31.6, 20.0, 13.6; HRMS (ESI-TOF) calcd for C<sub>25</sub>H<sub>26</sub>N<sub>3</sub>O<sub>5</sub><sup>+</sup> [M+H]<sup>+</sup>: 448.1867; found: 448.1867.

#### ***N*-butyl-6''-chloro-[2,2':3',3''-terpyridine]-6-carboxamide (4u)**



**4u** was prepared from **1a** (0.2 mmol, 51.0 mg) and 2-chloro-5-iodopyridine (0.6 mmol, 143.7 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a white solid (54.2 mg, 74% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.80 (dd, *J* = 4.7, 1.5 Hz, 1H), 8.35 (d, *J* = 2.4 Hz, 1H), 8.23 (d, *J* = 7.8 Hz, 1H), 8.12 (d, *J* = 7.7 Hz, 1H), 7.97 (t, *J* = 7.8 Hz, 1H), 7.78 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.50 (dd, *J* = 7.7, 4.7 Hz, 1H), 7.36 (dd, *J* = 8.2, 2.5 Hz, 1H), 7.25 (d, *J* = 8.2 Hz, 1H), 6.85 (t, *J* = 5.4 Hz, 1H), 3.31 – 3.24 (m, 2H), 1.50 – 1.43 (m, 2H), 1.37 – 1.30 (m, 2H), 0.96 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.5, 155.2, 154.0, 150.2, 149.3, 148.9, 148.4, 139.1, 138.8, 138.4, 135.6, 132.0, 126.6, 123.6, 123.6, 121.7, 38.9, 31.6, 20.1, 13.7; HRMS (ESI-TOF) calcd for C<sub>20</sub>H<sub>19</sub>ClN<sub>4</sub>NaO<sup>+</sup> [M+Na]<sup>+</sup>: 389.1140, found: 389.1140.


#### ***N*-butyl-3'-(thiophen-2-yl)-[2,2'-bipyridine]-6-carboxamide (4v)**



**4v** was prepared from **1a** (0.2 mmol, 51.0 mg) and 2-iodothiophene (0.6 mmol, 126.0 mg) according to the general procedure. After 24 hours, purification using preparative TLC (10:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a yellow oil (47.8 mg, 71% yield); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.70 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.12 (dd, *J* = 7.7, 0.9 Hz, 1H), 8.00 (dd, *J* = 7.8, 0.9 Hz, 1H), 7.92 (t, *J* = 7.7 Hz, 1H), 7.88 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.41 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.36 (s, 1H), 7.29 (d, *J* = 1.0 Hz, 1H), 6.95 (dd, *J* = 5.1, 3.6 Hz, 1H), 6.78 (dd, *J* = 3.5, 1.0 Hz, 1H), 3.33 – 3.27 (m, 2H), 1.52 – 1.46 (m, 2H), 1.36 – 1.31 (m, 2H), 0.94 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.0, 155.9, 154.7, 148.7, 148.6, 141.6, 139.5, 138.0, 129.9, 127.2, 126.7, 126.4, 126.0, 123.2, 121.4, 38.9, 31.6, 20.1, 13.8; HRMS (ESI-TOF) calcd for C<sub>19</sub>H<sub>20</sub>N<sub>3</sub>OS<sup>+</sup> [M+H]<sup>+</sup>: 338.1322, found: 338.1322.

## 2.5 Procedure for Synthesis of I-1 and I-2


### Synthesis of Complex I-1



**I-1**

To a vial equipped with a magnetic stir bar was charged with Pd(OAc)<sub>2</sub> (0.1 mmol, 22.4 mg), **1a** (0.1 mmol, 25.5 mg) and MeCN (1 mL). The solution was stirred at room temperature for 2 h. The reaction mixture was filtered, and the filter cake was collected and dried *in vacuo* to afford of complex **I-1** (35.6 mg, 85%) as a gold powder; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.29 (dd, *J* = 5.4, 1.0 Hz, 1H), 8.22 (d, *J* = 7.9 Hz, 1H), 8.12 (dd, *J* = 8.1, 1.8 Hz, 1H), 8.11 – 8.08 (m, 1H), 8.08 – 8.04 (m, 1H), 7.67 (dd, *J* = 7.1, 1.7 Hz, 1H), 7.49 – 7.45 (m, 1H), 3.16 – 3.10 (m, 2H), 2.16 (s, 3H), 1.64 – 1.57 (m, 2H), 1.45 – 1.37 (m, 2H), 0.96 (t, *J* = 7.4 Hz, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 178.1, 170.1, 155.2, 154.6, 152.9, 151.1, 140.6, 140.1, 127.2, 125.0, 123.0, 122.4, 45.7, 32.4, 23.6, 20.7, 14.1; HRMS (ESI-TOF) calcd for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>NaPd<sup>+</sup> [M+Na]<sup>+</sup>: 442.0353, found: 442.0357.

### Synthesis of Complex I-2





**I-2**

To a vial equipped with a magnetic stir bar was charged with  $\text{Pd}(\text{OAc})_2$  (22.5 mg, 0.1 mmol), **1b** (22.7 mg, 0.1 mmol) and MeCN (1 mL). The solution was stirred at room temperature for 2 h. The reaction mixture was filtered, and the filter cake was collected and dried *in vacuo* to afford of complex **I-2** (36.7 mg, 94%) as a gold powder;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.39 (d,  $J = 5.2$  Hz, 1H), 8.13 – 8.08 (m, 3H), 7.98 (dd,  $J = 8.0, 0.8$  Hz, 1H), 7.76 (dd,  $J = 7.8, 0.9$  Hz, 1H), 7.56 – 7.53 (m, 1H), 3.21 (q,  $J = 7.1$  Hz, 2H), 2.18 (s, 3H), 1.21 (t,  $J = 7.1$  Hz, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  178.3, 170.0, 155.6, 154.7, 153.0, 151.4, 140.6, 140.1, 127.4, 125.1, 122.5, 121.8, 40.5, 23.6, 15.1; HRMS (ESI-TOF) calcd for  $\text{C}_{15}\text{H}_{15}\text{N}_3\text{O}_3\text{NaPd}^+$   $[\text{M}+\text{Na}]^+$ : 414.0040 found: 414.0042.





**Crystal structure and data of N-butyl-3'-phenyl-[2,2'-bipyridine]-6-carboxamide (3a) (CCDC 1840936, Displacement ellipsoids are drawn at the 50% probability level.)**



Identification code	exp_5180
Empirical formula	C <sub>21</sub> H <sub>21</sub> N <sub>3</sub> O
Formula weight	331.41
Temperature/K	293(2)
Crystal system	monoclinic
Space group	P2 <sub>1</sub> /n
a/Å	12.3246(5)
b/Å	10.4302(5)
c/Å	14.0891(5)
α/°	90
β/°	98.191(4)
γ/°	90
Volume/Å <sup>3</sup>	1792.65(13)
Z	4
ρ <sub>calc</sub> /cm <sup>3</sup>	1.228
μ/mm <sup>-1</sup>	0.608
F(000)	704.0
Crystal size/mm <sup>3</sup>	0.21 × 0.2 × 0.19
Radiation	CuKα (λ = 1.54178)
2θ range for data collection/°	8.924 to 143.382
Index ranges	-15 ≤ h ≤ 14, -12 ≤ k ≤ 12, -10 ≤ l ≤ 17
Reflections collected	7029
Independent reflections	3420 [R <sub>int</sub> = 0.0209, R <sub>sigma</sub> = 0.0286]
Data/restraints/parameters	3420/0/228
Goodness-of-fit on F <sup>2</sup>	1.058
Final R indexes [I ≥ 2σ (I)]	R <sub>1</sub> = 0.0596, wR <sub>2</sub> = 0.1711
Final R indexes [all data]	R <sub>1</sub> = 0.0764, wR <sub>2</sub> = 0.1892
Largest diff. peak/hole / e Å <sup>-3</sup>	0.54/-0.25

**Crystal structure and data of I-2 (CCDC 1840935, Displacement ellipsoids are drawn at the 50% probability level.)**




**Table S1. Crystal data and structure refinement for I-2**

Identification code	exp_5179_pl_sq
Empirical formula	C <sub>15</sub> H <sub>15</sub> N <sub>3</sub> O <sub>3</sub> Pd
Formula weight	391.70
Temperature/K	293.15
Crystal system	triclinic
Space group	P-1
a/Å	8.8222(6)
b/Å	10.4866(7)
c/Å	10.6004(6)
α/°	100.088(5)
β/°	108.748(6)
γ/°	97.604(6)
Volume/Å <sup>3</sup>	895.39(11)
Z	2
ρ <sub>calc</sub> /g/cm <sup>3</sup>	1.453
μ/mm <sup>-1</sup>	8.485
F(000)	392.0
Crystal size/mm <sup>3</sup>	0.22 × 0.21 × 0.2
Radiation	CuKα (λ = 1.54178)
2θ range for data collection/°	8.746 to 143.332
Index ranges	-10 ≤ h ≤ 6, -12 ≤ k ≤ 12, -10 ≤ l ≤ 13
Reflections collected	5820
Independent reflections	3393 [R <sub>int</sub> = 0.0585, R <sub>sigma</sub> = 0.0679]
Data/restraints/parameters	3393/0/201
Goodness-of-fit on F <sup>2</sup>	1.083
Final R indexes [I ≥ 2σ (I)]	R <sub>1</sub> = 0.0571, wR <sub>2</sub> = 0.1550
Final R indexes [all data]	R <sub>1</sub> = 0.0629, wR <sub>2</sub> = 0.1629
Largest diff. peak/hole / e Å <sup>-3</sup>	1.33/-1.77


## 2.6 1 mmol-Scale Experiment of 3a


To a dried 10 mL Schlenk tube equipped with a magnetic stir bar were added 2,2'-bipyridin-6-carboxamide (1 mmol, 255 mg), iodobenzene (3 mmol, 612 mg), Pd(OAc)<sub>2</sub> (0.1 mmol, 22.5 mg), Cs<sub>2</sub>CO<sub>3</sub> (4 mmol, 1.3 g), mesitylene (3 mL). Then the tube was evacuated and back filled with nitrogen (10 times). The mixtures were stirred at 160 °C under a blanket of nitrogen. After 24 hours, the reaction was cooled to room temperature; the crude reaction mixture was diluted with DCM, washed with H<sub>2</sub>O and brine, dried over Mg<sub>2</sub>SO<sub>4</sub>. The organic phase was concentrated and purification using preparative TLC (8:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a colorless solid (245 mg, 74% yield).

## 2.7 Reversibility and KIE Study




In a clean oven dried tube equipped with a magnetic stir bar were added 2,2'-bipyridin-6-carboxamide (0.2 mmol, 51 mg), Pd(OAc)<sub>2</sub> (0.02 mmol, 4.5 mg), 0.25 ml D<sub>4</sub>-AcOH, mesitylene (1 mL). Then the tube was evacuated and back filled with nitrogen (10 times). The mixtures were stirred at 160 °C under a blanket of nitrogen. After 72 hours, the reaction was cooled to room temperature; the crude reaction mixture was diluted with DCM, washed with H<sub>2</sub>O and brine, dried over Mg<sub>2</sub>SO<sub>4</sub>. The organic phase was concentrated and purification using preparative TLC (8:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the product as a colorless solid (47 mg, 92% yield).







In a clean oven dried tube equipped with a magnetic stir bar were added the mixture of **1a** and D-**1a** (0.2 mmol), iodobenzene (0.6 mmol, 122.4 mg), Pd(OAc)<sub>2</sub> (0.02 mmol, 4.5 mg), Cs<sub>2</sub>CO<sub>3</sub> (0.8 mmol, 261 mg), mesitylene (2 mL). Then the tube was evacuated and back filled with nitrogen (10 times). The mixtures were stirred at 160 °C under a blanket of nitrogen. After 12 hours, the reaction was cooled to room temperature; the crude reaction mixture was diluted with DCM, washed with H<sub>2</sub>O and brine, dried over Mg<sub>2</sub>SO<sub>4</sub>. The organic phase was concentrated and dried. After 10 hours, and purification using preparative TLC (8:1 hexane: ethyl acetate and 5-10% Et<sub>3</sub>N) gave the starting material (7.1 mg, 14% yield) the product **3a** as a colorless solid (45.7 mg, 69% yield).







### 3. References



- Young, M. C.; Liew, E.; Ashby, J.; McCoy, K. E.; Hooley, R. J. *Chem. Commun.* **2013**, 49, 6331-6333.
- O'Duill, M. L.; Matsuura, R.; Wang, Y.; Turnbull, J. L.; Gurak, J. A., Jr.; Gao, D.-W.; Lu, G.; Liu, P.; Engle, K. M. *J. Am. Chem. Soc.* **2017**, 139, 15576-15579.

### 4. <sup>1</sup>H and <sup>13</sup>C NMR Spectra









































































8.637 8.635 8.634 8.632 8.628 8.626 8.624 8.622 7.707 7.702 7.699 7.696 7.689 7.476 7.469 7.465 7.458 7.452 7.444 7.438 7.434 7.426 7.394 7.390 7.378 7.375 7.363 7.359 7.244 7.241 7.235 7.230 7.224 7.220 7.216 7.215 7.166 7.160 7.157 7.151 7.147 7.109 7.107 7.099 7.097 7.094 7.092 7.084 7.082 6.892 6.876 6.874 0.000



3m



159.213

149.364

141.311

140.586

139.420

135.169

130.457

130.443

128.491

128.018

127.607

126.660


125.377

121.308

77.254

77.000

76.746



3m

